BioVie Inc. (BIVI) Earnings Call Transcripts

BioVie Inc.'s Latest Earnings Call - June 2, 2026

In the Q2 2026 earnings call, BioVie Inc. (BIVI:US) highlighted significant advancements in its clinical pipeline, particularly with its lead asset, bezisterim. The company reported no revenue for the quarter, consistent with previous periods, and maintained its cash position, which is expected to last through the end of the year. Management emphasized two imminent data readouts for Parkinson's and long COVID trials, which could serve as catalysts for stock movement, with potential annual sales projections of $3-5 billion for Parkinson's and over $10 billion for long COVID in the U.S. alone.

Reported metrics

Guidance from management

Management did not provide specific revenue guidance but emphasized the potential for significant sales opportunities in the coming years based on upcoming trial results.

What management said

I wish I had the most updated chart on that to show that in one place the numbers, I do not. But let me give you the numbers, right? We believe that ascites could be a $1.5 billion to $2 billion annual sales drug in the U.S. alone. We believe that Parkinson's could be a $3 billion to $5 billion annual sales drug in the U.S. alone. Long COVID could represent a $10 billion annual sales in the U.S. And of course, Alzhei...

That's a very tough question to answer, but let me give you a ballpark. Based upon what we know now and what we have modeled out, we believe that Alzheimer's trial could take $25 million to $30 million to conduct. That's one trial, and we would need to conduct 2 of them, right? So the total cost to bring bezisterim to market for Alzheimer's would be $50 million to $60 -- and that's part of the reason why the program...

What analysts pressed on

Analysts expressed concerns about the high placebo effect in Parkinson's trials and the need for robust data to mitigate this risk. There were also inquiries about the costs associated with future Alzheimer's trials, which management estimated at $50-60 million for completion.

Main topics on the call

• Clinical Trial Updates — Management confirmed that the top line readout for the Parkinson's trial is expected in late July to early August, while the long COVID trial results are anticipated by late August to early September. Cuong Do stated, "W...
• Bezisterim's Mechanism of Action — Cuong Do explained bezisterim's unique approach in treating neurodegenerative diseases by addressing inflammation and insulin resistance, stating, "We believe that future treatments should address both motor and non-moto...
• Market Potential — The company estimates significant market opportunities, projecting $3-5 billion for Parkinson's and over $10 billion for long COVID in annual U.S. sales. Management highlighted, "We believe BioVie represents a terrific o...
• Regulatory Strategy — BioVie is preparing to approach the FDA for potential accelerated approval for its long COVID treatment based on promising trial data. Cuong Do noted, "If we get the promising results... this would allow us to go to the ...

Read the full BioVie Inc. transcript (June 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 9 BioVie Inc. earnings call transcripts on record, spanning June 26, 2024 to August 12, 2026. Based on this history, BioVie Inc. reports quarterly. The most recent call on file is dated August 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BIVI

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

9

First call

June 26, 2024

Most recent

August 12, 2026

Reporting cadence

quarterly